SCHEMBL24124322

SCHEMBL24124322

O=C1CSc2ccc(C(=O)Nc3ccc(S(=O)(=O)Nc4ccccc4)cc3)cc2N1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 8/20 0.75
▸ MAPT P10636 7/20 0.75
▸ MEN1 O00255 7/20 0.75
▸ HTT P42858 6/20 0.75
▸ ALDH1A1 P00352 6/20 0.75
▸ LMNA P02545 5/20 0.75
▸ SMN1; SMN2 Q16637 4/20 0.75
▸ MAPK1 P28482 2/20 0.75
▸ NPSR1 Q6W5P4 2/20 0.75
▸ KDM4E B2RXH2 3/20 0.61
▸ NPC1 O15118 2/20 0.61
▸ GPR27 Q9NS67 1/20 0.57
▸ NOD2 Q9HC29 1/20 0.54
▸ USP2 O75604 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ CYP2C9 P11712 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27179487 0.86 MEN1 (1.00) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL30788263 0.86 MEN1 (1.00) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL25921128 0.82 GPR27 (0.60) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL24125017 0.81 MAPT (0.55) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL24124917 0.81 POLB (0.60) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL24125099 0.80 RAB9A (0.62) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL25920723 0.80 RAB9A (0.62) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL24125086 0.80 RAB9A (0.62) KMT2AMAPTMEN1HTTALDH1A1
SCHEMBL25920730 0.80 ALDH1A1 (0.57) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL24125233 0.80 HTT (0.60) KMT2AMAPTMEN1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 KMT2A 578/4885MAPT 4492/4885MEN1 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback